



SPECIAL OPERATIONS/
LOW-INTENSITY CONFLICT

OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE
WASHINGTON, D.C. 20301-2500

14 MAR 2003

MEMORANDUM FOR DEPUTY ASSISTANT SECRETARY OF THE NAVY
(PERSONNEL PROGRAMS)

SUBJECT: LSD Confirmation Testing Within the Navy Drug Testing Program

The Navy is currently authorized to identify sailors who have used Lysergic Acid Diethylamide (LSD) by testing their urine for the parent drug, LSD. Two tests are required, an initial immunoassay test and a confirmation test for LSD by gas chromatography/mass spectrometry. This memorandum authorizes the Navy to also confirm LSD use by testing for the presence of 2-oxo-3-hydroxyLSD metabolite in urine. The identity and concentration of 2-oxo-3-hydroxyLSD must be determined using gas or liquid chromatography with a mass spectrometer or a tandem mass spectrometer for detection. The urine concentration of 2-oxo-3-hydroxyLSD must be equal to or greater than one (1) nanogram per milliliter to confirm that the donor used LSD.

Prior to implementing a confirmation test for 2-oxo-3-hydroxyLSD, each laboratory is required to validate the method as directed by the Armed Forces Institute of Pathology (AFIP) and receive certification from my Office. Each laboratory must also participate in the AFIP proficiency program to maintain certification.

This authorization does not change the current requirement for a valid initial test for LSD. It also does not preclude the Navy from using other currently approved methods to confirm the use of LSD. My point of contact is Colonel Mick Smith, at telephone (703) 697-5607, email mick.smith@osd.mil.

A handwritten signature in cursive script, reading "André D. Hollis".

André D. Hollis
Deputy Assistant Secretary of Defense for
Counter narcotics